This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (46)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Michael M. Lederman, MD; Adam Penn-Nicholson, BA; Michael Cho, PhD; Donald Mosier, MD, PhD

JAMA. 2006;296:815-826.

Chemokine receptors are found on cell surfaces and promote cellular migration by chemotaxis. The CC chemokine receptor 5 (CCR5) is used by the human immunodeficiency virus (HIV) to infect cells. Strategies that target human CCR5 are therefore being developed to prevent and treat HIV infection. Antiviral strategies that target a host element necessary for viral replication may be predicted to interfere with the function of that element and may therefore adversely affect the host. We conducted a review of the literature between November 2005 and April 2006 with a focus on articles addressing the genetics and function of CCR5, the effects of CCR5 deletion in human and murine systems, and treatment strategies for HIV infection that target this coreceptor. English-language articles in the human and murine literature published between March 1996 and April 2006 were identified through a search of MEDLINE using CCR5 as the search term. Relevant articles as judged by their titles and abstracts were reviewed in detail. In addition, based on our knowledge of the field and with permission, unpublished work was also reviewed. In this article, we explore the effects that targeting CCR5 may have on host defenses in individuals with immunity already compromised by HIV infection.

Author Affiliations: Center for AIDS Research, Case Western Reserve University School of Medicine, University Hospitals of Cleveland, Cleveland, Ohio (Drs Lederman and Cho and Mr Nicholson); and Scripps Research Institute, La Jolla, Calif (Dr Mosier).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Anti-HIV-1 Therapeutics: From FDA-approved Drugs to Hypothetical Future Targets
Adamson and Freed
Mol. Interv. 2009;9:70-74.
ABSTRACT | FULL TEXT  

The Relative Activity of "Function Sparing" HIV-1 Entry Inhibitors on Viral Entry and CCR5 Internalization: Is Allosteric Functional Selectivity a Valuable Therapeutic Property?
Muniz-Medina et al.
Mol. Pharmacol. 2009;75:490-501.
ABSTRACT | FULL TEXT  

Ku70, an essential gene, modulates the frequency of rAAV-mediated gene targeting in human somatic cells
Fattah et al.
Proc. Natl. Acad. Sci. USA 2008;105:8703-8708.
ABSTRACT | FULL TEXT  

CCL5-mediated T-cell chemotaxis involves the initiation of mRNA translation through mTOR/4E-BP1
Murooka et al.
Blood 2008;111:4892-4901.
ABSTRACT | FULL TEXT  

Anti-HIV Activity and Resistance Profile of the CXC Chemokine Receptor 4 Antagonist POL3026
Moncunill et al.
Mol. Pharmacol. 2008;73:1264-1273.
ABSTRACT | FULL TEXT  

Identification of a Postendocytic Sorting Sequence in CCR5
Delhaye et al.
Mol. Pharmacol. 2007;72:1497-1507.
ABSTRACT | FULL TEXT  

G Protein-Coupled Receptor Trafficking in Health and Disease: Lessons Learned to Prepare for Therapeutic Mutant Rescue in Vivo
Conn et al.
Pharmacol. Rev. 2007;59:225-250.
ABSTRACT | FULL TEXT  

Coreceptor Switch in R5-Tropic Simian/Human Immunodeficiency Virus-Infected Macaques
Ho et al.
J. Virol. 2007;81:8621-8633.
ABSTRACT | FULL TEXT  

Explaining, predicting, and treating HIV-associated CD4 cell loss: after 25 years still a puzzle.
Henry et al.
JAMA 2006;296:1523-1525.
FULL TEXT